Article
19 Feb 2021
NATIERRA: Presenting Fresh Evidence On Appeal
AUTHORS CONTENT
Article
05 Feb 2021
Federal Court Upholds Patent Validity And Issues Declarations Of Infringement Against Two Generic Apixaban Tablets
Article
18 Jan 2021
Divided Success In PM(NOC) Actions Regarding Glatiramer Acetate
Article
11 Jun 2020
Federal Court Determines That Infringement Action Under PM(NOC) Regulations Is Not Moot Where Trial Proceeds After Patent Expiry
Article
19 May 2020
Be Careful How You Ask – Canadian Court Considers Demand Letters
Article
18 May 2020
No Leave Required For Experimental Testing Conducted Prior To Litigation
Article
07 Apr 2020
PM(NOC) Statutory Deadlines Still Applicable
Article
06 Apr 2020
Gestion des marques en ligne : éviter les influenceurs toxiques
Article
27 Mar 2020
Online Brand Management: Avoiding Toxic Social Influencers
Article
29 May 2019
Federal Court Re-Visits The Test For Protective Orders
Article
27 May 2019
Impact Of Trade-Marks Act Amendments On Pharmaceutical Brand Owners
Article
21 Dec 2018
Further Trademark Amendments Are Here — Bill C-86 Is Given Royal Assent
Article
19 Dec 2018
Bill C-86 Receives Royal Assent, Bringing Amendments Across Canada's IP Statutes
Article
09 Nov 2018
IP Monitor - Don't Be Afraid! Our Guide To The IP Tricks And Treats In A Hallowe'en Budget Bill
Article
08 Nov 2018
Bill C-86 — Significant Changes To Canada's IP Regime
Article
13 May 2017
Pharma In Brief - Federal Court Comments On The Admissibility Of 'But For' World S. 8 Evidence And Rejects Generic Pipefill Claim
Article
27 Apr 2017
Important Benefits For Canadian Trademark Registrations
Article
21 Apr 2017
Pharma In Brief - Federal Court Comments On The Admissibility Of 'But For' World S. 8 Evidence And Rejects Generic Pipefill Claim
Article
03 Mar 2017
Pharma In Brief - TMOB Dismisses Section 45 Proceedings For The Trade-Mark REMODULIN
Article
23 Feb 2017
Pharma In Brief - Supreme Court Dismisses Leave To Appeal Regarding Hearsay Evidence In Venlafaxine s. 8 Case